# Abbott Next Generation Drug Eluting Stent 48mm Study

Study · id `cardio:ct-nct04282148` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04282148](<https://clinicaltrials.gov/study/NCT04282148>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04282148

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 107 participants.

## Technical summary

Registry record NCT04282148. Allocation not applicable; no masking; primary purpose treatment. Start 2020-06-17 (actual); primary completion 2022-10-05 (actual). Results posted on 2024-02-12.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 107 participants (enrolled count; ClinicalTrials.gov record NCT04282148, source copy `cardio:ctgov-nct04282148-2025-01-08`, retrieved 2026-10-26)
- Started: 2020-06-17 (actual) (ClinicalTrials.gov record NCT04282148, source copy `cardio:ctgov-nct04282148-2025-01-08`, retrieved 2026-10-26)
- Primary completion: 2022-10-05 (actual) (ClinicalTrials.gov record NCT04282148, source copy `cardio:ctgov-nct04282148-2025-01-08`, retrieved 2026-10-26)
- Completion: 2023-09-17 (actual) (ClinicalTrials.gov record NCT04282148, source copy `cardio:ctgov-nct04282148-2025-01-08`, retrieved 2026-10-26)
- Results first posted: 2024-02-12 (ClinicalTrials.gov record NCT04282148, source copy `cardio:ctgov-nct04282148-2025-01-08`, retrieved 2026-10-26)
- Countries: United States; Australia; Taiwan (ClinicalTrials.gov record NCT04282148, source copy `cardio:ctgov-nct04282148-2025-01-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04282148-2025-01-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Abbott Next Generation Drug Eluting Stent 48mm Study
- Acronym: SPIRIT 48
- Condition: Coronary Artery Disease
- Intervention (Device): ABT NG DES 48 EECSS
- Lead sponsor: Abbott Medical Devices
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Abbott (`cardio:abbott`)

## Provenance

Content hash: 18e992a2c728ea6869b73d47ef995c53f506516ef0cecb33e747eb0872709dfa
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
